Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

BACKROUND: Patients with metastatic endometrial carcinoma have a poor prognosis and PIK3CA mutations and amplifications are common in these cancers. This study evaluated the efficacy and safety of the pure PI3K inhibitor BKM120 in advanced or recurrent endometrial carcinoma. METHODS: This phase II,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Heudel, P-E, Fabbro, M, Roemer-Becuwe, C, Kaminsky, M C, Arnaud, A, Joly, F, Roche-Forestier, S, Meunier, J, Foa, C, You, B, Priou, F, Tazi, Y, Floquet, A, Selle, F, Berton-Rigaud, D, Lesoin, A, Kalbacher, E, Lortholary, A, Favier, L, Treilleux, I, Ray-Coquard, I
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5294485/
https://ncbi.nlm.nih.gov/pubmed/28072765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.430
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados